Latest News and Press Releases

Präsentationen zeigen Fortschritte in BioNTechs spätklinischen Programmen im Bereich Lungenkrebs und unterstreichen das Potenzial des differenzierten Unternehmensportfolios, welches Immunmodulatoren,...

Presentations showcase progress in BioNTech’s late-stage lung cancer programs, reinforcing the potential of the Company’s differentiated portfolio spanning immunomodulators, antibody-drug conjugates,...

-- Study Results Support the use of TellDx to Personalize Cancer Care Management – -- Clinical study published in Cancer Discovery -- ANDOVER, Mass., Jan. 14, 2026 (GLOBE NEWSWIRE) -- TellBio,...

Precede Biosciences Presents New Data Demonstrating Its Liquid Biopsy Platform’s Ability to Resolve Target Expression and Molecular Subtypes in SCLC

Daten zur Kombination des bispezifischen PD-L1xVEGF-A-Antikörper-Kandidaten Pumitamig (BNT327/BMS986545) mit Chemotherapie zeigen weiterhin ermutigende Anti-Tumor-Aktivitäten bei Patientinnen und...

PD-L1xVEGF-A bispecific antibody pumitamig (BNT327/BMS986545) plus chemotherapy continues to show encouraging antitumor activity in patients with extensive-stage small cell lung cancer (”ES-SCLC”),...

–  Systemic administration of Olvi-Vec in the initial dose escalation cohorts achieved a 71% disease control rate (5/7) with two partial responders. All participants with disease control experienced a...

Wilmington, Delaware, Transparency Market Research Inc. –, Jan. 17, 2025 (GLOBE NEWSWIRE) -- The global lung cancer diagnostics market is projected to experience substantial growth in the coming...

Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update

Pune, India, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Lung cancer now a days is treated by targeted therapy, a type of personalized medicine, is a combination of two or more drugs, designed to directly...